Stoke Therapeutics, Inc.

NASDAQ:STOK

15.14 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 4.8314.2162.8023.308-2.4815.1523.2692.9053.23130000000000000000
Cost of Revenue 1.111.1131.2151.21.1671.1471.1520.9240.8350.6240.6210.5760.5260.507000000000000
Gross Profit 3.7213.1031.5872.108-3.6484.0052.1171.9812.3962.376-0.621-0.576-0.526-0.507000000000000
Gross Profit Ratio 0.770.7360.5660.6371.470.7770.6480.6820.7420.7920000000000000000
Reseach & Development Expenses 20.58821.80521.15420.27120.55119.63121.06120.10918.35818.30915.80214.35814.0959.9138.9048.1097.9687.2157.0896.5186.0234.1333.0042.2271.8881.252
General & Administrative Expenses 13.03710.2210.6110.27110.2310.2119.3839.94410.1119.4868.7248.3257.9346.9145.6825.6025.0444.523.9793.3242.4222.1891.5381.091.1220.66
Selling & Marketing Expenses -0.562-0.55-0.59100000000000000000000000
SG&A 12.4759.6710.01910.27110.2310.2119.3839.94410.1119.4868.7248.3257.9346.9145.6825.6025.0444.523.9793.3242.4222.1891.5381.091.1220.66
Other Expenses -0.048-0.4280.0410.0410.0410.0420.0410.0420.0420.0420.0420.0420.0280.0160.0150.0160.0030.0220.0040.002-0.00300000
Operating Expenses 33.06331.47531.17330.54230.78129.84230.44430.05328.46927.79524.52622.68322.02916.82714.58613.71113.01211.73511.0689.8428.4456.3224.5423.3173.011.912
Operating Income -29.342-28.372-29.586-27.234-33.262-20.442-27.175-27.148-25.238-24.795-24.526-22.683-22.029-16.827-14.586-13.711-13.012-11.735-11.068-9.842-8.445-6.322-4.542-3.317-3.01-1.912
Operating Income Ratio -6.074-6.73-10.559-8.23313.407-3.968-8.313-9.345-7.811-8.2650000000000000000
Total Other Income Expenses Net 3.6471.9982.6280.0410.041-2.1031.521.0370.5860.1460.0420.0420.0280.0160.0150.0160.0030.0220.0040.002-0.0030.580.26000
Income Before Tax -25.695-26.374-26.958-24.542-30.654-22.545-25.655-26.111-24.652-24.649-24.448-22.597-21.967-16.793-14.561-13.684-12.959-11.039-10.16-8.604-7.819-5.742-4.282-3.317-3.01-1.912
Income Before Tax Ratio -5.319-6.256-9.621-7.41912.356-4.376-7.848-8.988-7.63-8.2160000000000000000
Income Tax Expense 01.0710.714-3.288-3.178-4.248-3.608-2.032-1.432-0.25-0.078-0.044-0.034-0.254-0.01-0.245-0.05-0.674-0.904-1.362-0.62900000
Net Income -25.695-26.374-26.958-24.542-30.654-18.297-22.047-24.079-23.22-24.399-24.448-22.597-21.967-16.793-14.561-13.684-12.959-11.039-10.16-8.604-7.819-5.742-4.282-3.317-3.01-1.912
Net Income Ratio -5.319-6.256-9.621-7.41912.356-3.551-6.744-8.289-7.187-8.1330000000000000000
EPS -0.46-0.57-0.6-0.55-0.69-0.43-0.56-0.61-0.59-0.65-0.66-0.61-0.6-0.46-0.44-0.41-0.39-0.34-0.31-0.26-1.54-0.19-0.18-0.14-0.13-0.081
EPS Diluted -0.46-0.57-0.6-0.55-0.69-0.43-0.56-0.61-0.59-0.65-0.66-0.61-0.6-0.46-0.44-0.41-0.39-0.34-0.31-0.26-1.54-0.19-0.18-0.14-0.13-0.081
EBITDA -28.232-27.259-28.371-27.234-33.262-24.69-27.175-26.76-25.238-24.548-24.526-22.429-21.78-16.827-14.349-13.711-12.788-11.542-10.929-9.842-8.34-6.242-4.467-3.253-2.967-1.88
EBITDA Ratio -5.844-6.466-10.125-8.23313.407-4.792-8.313-9.212-7.811-8.1830000000000000000